Combination of Minimal Residual Disease on Day 15 and Copy Number Alterations Results in BCR-ABL1-negative pediatric B-ALL: A powerful tool for prediction of induction failure

Acute Lymphoblastic Leukemia (ALL) is the most frequent malignancy in pediatric aged 0 to 14 years all over the world.[1] In pediatrics with B-cell ALL (B-ALL), advances in risk stratification and innovative therapeutic approaches have drastically improved treatment outcomes with the five-year survival rate of above 90% in high-income countries.[2,3] About 75% of pediatric ALL cases have a recurring chromosomal alteration that can be detected by karyotyping, Fluorescence In Situ Hybridization (FISH), or molecular methods.

Source: Cancer Genetics and Cytogenetics - December 21, 2023 Category: Genetics & Stem Cells Authors: Hamed Baghdadi, Masoud Soleimani, Mahdi Zavvar, Gholamreza Bahoush, Behzad Poopak Source Type: research